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Abstract:  Attention to COPD is increasing worldwide because its high prevalence, morbidity, 
and mortality present a challenging problem for all healthcare systems. The burden of COPD, 
which is usually measured in terms of progressive lung function decline, impact on patients’ 
symptoms, patient’s disability, and quality of life, together with the corresponding use of health 
care resources, is still a major aspect of the disease. Recommendations to treat COPD according 
to the most accepted guidelines have expanded in recent years even though COPD still remains 
unacceptably under-diagnosed and under-treated worldwide. Obviously, more severe degrees of 
COPD receive major attention both in terms of monitoring of clinical outcomes and of assessing 
the economic value of therapeutic interventions. The role of different strategies against COPD 
should be valued on the basis of their effectiveness in outcome optimization, which primarily 
depends on the efﬁ  cacy of prevention activities and of early diagnosis programs. It is generally 
agreed that the main proportion of COPD burden still depends on the clinically uncontrolled 
disease and on its high exacerbation rate, which frequently leads to the patient hospitalization. 
In COPD, the effects of guideline recommendations have been only sporadically investigated 
in pharmaoeconomic terms, even though symptoms and disability have declined substantially; 
the corresponding improvement in quality of life, and a signiﬁ  cant decrease in both direct and 
indirect costs have been proved to depend on appropriate rehabilitative and pharmacological 
long-term treatment of the disease. At present, more precise indices and more ﬁ  tting outcomes 
are continuously sought and found in order to assess more effective strategies for controlling 
COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by a 
not fully reversible airﬂ  ow limitation which leads to a progressive functional decline, 
with cigarette smoking being the major risk factor (WHO 1998). Results of all epi-
demiological studies prove that the prevalence of respiratory symptoms is higher in 
smokers than in non-smokers, and that COPD prevalence increases with age (Silverman 
and Speizer 1996). Other factors responsible for the high prevalence and incidence of 
COPD are the increasing mean age of populations together with persistent and ever 
increasing environmental pollution (Silverman and Speizer 1996; Murray and Lopez 
1997; Viegi et al 2001).
COPD is the fourth leading cause of death (Murray and Lopez 1997; WHO 1998) 
and one of the main causes of disability in the world, particularly in developed 
countries. COPD is the chronic respiratory disease that represents the most signiﬁ  cant, 
and ever increasing, world-wide public health problem; its epidemiological, clinical, 
social, and economic impact will increase in the near future (Lee et al 2006), making 
it the third most important cause of death in the next 10–15 years (Murray and 
Lopez 1997).International Journal of COPD 2008:3(1) 2
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The GOLD guidelines classify disease severity in 
different stages based on clinical symptoms – forced expira-
tory volume in one second (FEV1) and forced vital capacity 
(FVC). Their main goal is to increase awareness of COPD, 
and decrease morbidity (such as GP visits, ER visits, hospi-
talizations) and mortality due to the disease (GOLD 2003, 
2004; Miller et al 2005).
Epidemiology of costs
Chronic respiratory diseases concern a large number of 
subjects and generate important health and social costs. 
The global impact of these diseases, in particular COPD, is 
the subject of an increasing number of pharmacoeconomic 
studies published over the last few years (Dal Negro et al 
2002; Rennard et al 2002; Miller et al 2005; Chapman 
et al 2006).
In particular, concerns about COPD are quite recent 
compared with bronchial asthma (Skrepnek and Skrepnek 
2004; Chapman et al 2006), and the overall impact of COPD 
was properly understood only a few years ago when all 
international scientiﬁ  c institutions emphasized the burden 
of COPD mainly due to its growing prevalence and increas-
ingly alarming incidence (Murray and Lopez 1997; European 
Lung White Book 2003; Halbert et al 2003; Lee et al 2006). 
COPD represents an enormous health problem for the com-
munities: patients and their families, the workplace, health 
institutions, and society as a whole are heavily affected by 
the disease (Minkoff 2005).
In general, the impact of COPD has been proven to be 
high in all countries, particularly in most industrialized 
countries.
In the US, the country that ﬁ  rst oriented studies on COPD, 
the total annual cost of COPD has been estimated at nearly 
US$24 billion in 1993, more than 60% of which is due 
to direct costs, 18% to early death, and 20% to morbidity 
(Sullivan et al 2000). In 2000, total annual cost of COPD in 
the US had increased by more than 30%, reaching US$31 
billion, with a substantial increase in indirect costs (Ramsey 
and Sullivan 2004). A further increase was assessed in 2004, 
with an estimated cost of US$37.2 billion (National Heart, 
Lung, and Blood Institute 2004). COPD annual direct costs 
per patient depend on the clinical severity of the disease, 
ranging from US$1681 for mild to US$10,812 for severe 
COPD (Hilleman et al 2000).
In an Italian bottom-up study carried out on a sample 
of the general population corresponding to more than 5 
million inhabitants and aimed to assess the cost of COPD, 
the mean annual cost per patient was  2100, ranging from 
1500 for milder clinical stages (65% of cases) to  3900 for 
most severe cases (5% of cases) of COPD (Skrepnek and 
Skrepnek 2004).
A further nation-wide survey in 2003 based on telephone 
interviews, the cost was conﬁ  rmed to vary as a function of 
clinical severity of COPD, reaching  7000/patient/year in 
the most severe cases. Hospital admission has been found to 
account for 75% of the total cost (Dal Negro et al 2003a).
As assessed in the US and in Italy, mean annual cost of 
COPD has progressively increased over the last few years, 
increasing by 35% to reach an average of  2720/patient 
(Dal Negro et al 2008).
Direct costs for COPD were shown to be correspond-
ingly high also in the Netherlands, where the annual cost 
per patient of managing COPD is almost 3 times as high 
as that of asthma (Rutten van Molken and Feenstra 2001; 
Oostenbrink et al 2004). Similar results were obtained also in 
France, where total medical consumption of COPD patients 
was  3.5 billion, which accounted for 3.5% of total medical 
expenditure (Detournay et al 2004). Similar results have been 
shown for Spain (Miravittles et al 2002; Masa et al 2004), 
the UK, Ireland (Tynan and Lane 2005; Halpin 2006), and 
Sweden (Jacobson et al 2000), thus conﬁ  rming that COPD 
represents a common but increasing problem in all western 
countries, with different healthcare systems.
The impact of COPD has been assessed also in Far East 
countries. In Japan, the estimated total annual cost of COPD 
corresponded to US$6.8 billlion, mainly due to direct costs 
related to most severely affected patients (mean per patient 
cost US$3694) (Nishimura and Zaher 2004).
Similar data were also obtained from other studies carried 
out in different Asian and African countries (Chan-Yeung 
et al 2004).
As estimates of the economic impact of the disease are 
important for allocating resources, the future COPD eco-
nomic impact should be estimated periodically by means of 
pharmacoeconomic surveys (bottom-up or top-down), or by 
means of health economic models in order to orient future 
interventional strategies with higher precision and maximize 
the value of resource allocation. Data from these studies 
suggest that the projected annual cost (US$) for COPD in 
the US will increase from 176.8 to 389.2 to 832.9 billion in 
the next 5, 10, and 20 years, respectively (Lee et al 2006), 
further pinpointing the dramatic impact of COPD also for 
the future generations.
In all studies on pharmcoeconomics of COPD, different 
cost perspectives have been adopted: the patient perspective, 
by assessing only indirect costs (such as lost productivity International Journal of COPD 2008:3(1) 3
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of the patient and his/her ﬁ  rst-degree relatives); the health 
service perspective, by calculating only direct costs (such as 
hospitalizations, medical visits and examinations, pharma-
ceutical treatments, rehabilitation); and the societal perspec-
tive, by taking into account both direct and indirect costs.
Data from all studies are conﬁ  rming the high proportion 
of direct costs mainly due to hospitalizations and the increas-
ing impact of indirect costs of COPD. Moreover, while direct 
costs are driven mainly by exacerbations of COPD, which 
represent the most important cause of hospitalization in all 
countries, the costs for the diagnostic and the investigational 
approach to the disease still represent a negligible propor-
tion of total healthcare costs (5%–6% only) (Britton 2003; 
Dal Negro et al 2008). Furthermore, direct costs due to 
pharmacological treatments tend in general terms to reﬂ  ect 
the current largely inadequate approach to and the undertreat-
ment of COPD (Dal Negro et al 2002; Rennard et al 2002; 
Chapman 2006).
The outcomes
Although pharmacoeconomic studies can recognize dif-
ferent experimental designs, nevertheless they conﬁ  rm the 
elevated and ever growing impact of COPD in all countries, 
from both the perspective of patients and their families, and 
of society as a whole.
The impact of COPD can be investigated by assessing 
and monitoring several indices which should inform on the 
real burden of the disease for the patient and the health care 
system, and provide the evidence that should contribute to 
improving the management of the disease at a personal and 
societal level.
As COPD affects the patient’s life substantially even 
in the earliest stages, some outcomes will be related to the 
personal and subjective perceptions of the disease, such as 
symptoms, disability, and quality of life; other indicators will 
be related more to the patient’s objective conditions which can 
progressively deteriorate, such as lung function, absenteeism, 
frequency and severity of exacerbation, number of hospital 
admissions, and mortality (Anto et al 2001; Viegi et al 2001; 
Rennard et al 2002; Miller et al 2005).
Unfortunately, as these outcomes reveal different sensi-
tivities and prove variably related, the precise detection of 
COPD effects can represent an issue difﬁ  cult to clarify in 
real life.
The subject’s perception of disease severity and disease 
severity as indicated by speciﬁ  c breathlessness scales can dif-
fer signiﬁ  cantly. It has been demonstrated that many COPD 
subjects tend to underestimate the severity of their condition 
and deﬁ  ne as mild or moderate their dyspnea even if they 
scored objectively the highest levels on the Medical Research 
Council dyspnea scale (Rennard et al 2002). Furthermore, 
females rate their dyspnea higher than males despite their 
reduced smoking habit (Rennard et al 2002), thus conﬁ  rming 
the intrinsic variability of this outcome.
COPD is deﬁ  ned as a disease condition characterized 
by a progressive and not fully reversible airﬂ  ow limitation. 
Recently it has been shown that a variable proportion of 
COPD patients (20%–40%) prove reversible in terms of lung 
function, even though at a different extent, and depending on 
the functional indicator used (Calverley et al 2003a). More-
over, the absence of reversibility, such as in terms of FEV1, 
does not correspond at all to a complete unresponsiveness 
to bronchodilators or other therapeutic strategies. Actual 
changes in FEV1 following bronchodilators can be small but 
are often accompanied by larger changes in lung volumes, 
which contribute to a reduction in perceived breathlessness 
(Celli and MacNee 2004). In these circumstances an increase 
in lung volume and in inspiratory capacity can represent 
much more ﬁ  tting indicators than FEV1 for a substantial 
improvement in clinical signs (such as breathlessness, or exer-
cise tolerance, or health status) as referred by the patient.
The use of only one global outcome with the aim of sum-
marizing effectively and synthetically all events related to 
COPD has been more or less abandoned due to the multifacto-
rial expression of the disease. A combination of humanistic, 
lung function, and clinical parameters are usually combined 
with measures of quality of life in order to obtain a much 
more ﬁ  tting proﬁ  le of the burden of COPD.
Obviously, survival can be regarded as the strongest 
outcome, but it represents an a posteriori outcome from the 
patient’s perspective, even though it is of a great strategic 
value from both health care system and societal perspec-
tives.
Other outcomes, the intermediate outcomes, are closer 
to the patient’s belief (such as, symptom relief, absenteeism, 
and exacerbations), and characterized by a high prognostic 
value (D’Souza et al 2006). Even though a unique deﬁ  ni-
tion of COPD exacerbation is not yet available and widely 
accepted (D’Souza et al 2006), exacerbations are regarded 
as an important intermediate outcome from all perspectives. 
Their frequency and clinical severity, the time interval for a 
new COPD exacerbation, together with data on the amount 
of health resources needed for their control and data on 
indirect costs contribute to provide a useful method for 
assessing and comparing the effects of different therapeutic 
interventions.International Journal of COPD 2008:3(1) 4
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Quality adjusted life expectancy measure (Golmohammadi 
and Jakobs 2004) and disability adjusted life years (DALY) 
(Lopez and Murray 1998) are also measures used to assess 
the burden of COPD even though these particular outcomes 
are much more relevant to the most severe cases of the 
disease: in other words, they are regarded as particularly 
reliable for those patients who are more disabled and limited 
by COPD.
Outcomes optimization
Because of the ever growing need to reconcile the limited 
economic resources available with the increasing demand 
for well-being by the general population, health services of 
industrialized countries have been devoting more and more 
attention to the costs generated by healthcare in their own 
territories.
Cost of illness (COI) analysis by measuring and esti-
mating the resources consumed in disease management is 
a useful methodological tool that broadens the criteria for 
evaluating the effects of a given disease, because it pro-
vides information about the economic (as well as clinical) 
effects of the disease on the entire “health system” (Ofman 
et al 2004).
On the basis of the epidemiological and pharmacoeco-
nomic evidence described above, the main tools for outcomes 
optimization in COPD should be:
- prevention;
- early  diagnosis;
-  reduction in hospital costs;
-  treatment of disability;
- pharmacological  treatments.
Prevention
Prevention is certainly the key point of outcome optimization. 
It should be oriented ﬁ  rst to the avoidance of the main disease 
risk factors (such as tobacco smoke). Smoking cessation is 
known to represent the only intervention able to delay disease 
progression, and programs for smoking cessation are known 
to be effective for COPD, but also against all other related 
disease (such as cardiovascular diseases and lung cancer). 
These programs are effective also in economic terms. A 
study carried out on children (0–12 years) living in families 
with smokers and oriented to the assessment of avoidable 
costs, showed that smoking abatement led to a progressive 
and substantial amount of savings following the ﬁ  rst and 
second year of the program (US$338 and US$991 annually 
per patient, respectively) (Peters et al 1998). These programs 
proved also cost-effective in terms of reducing mortality from 
all causes (Godtfredsen et al 2002a) and reducing hospital 
admissions (Godtfredsen et al 2002b). It should be considered 
that even though these programs, usually combined with 
speciﬁ  c educational programs for smoking cessation, provide 
only long-term results, they likely represent the only effective 
programs for countering the increasing prevalence of COPD 
in the near future and the corresponding huge increase of 
health care costs (Feenstra et al 2001; Lee et al 2006).
Reduction in occupational risk factors would also repre-
sent a cost-effective approach, as demonstrated a few years 
ago in the US: the total cost related to occupational factors 
ranged from US$3.3 to 6.6 billion, comprising direct costs 
due to hospitalizations (57%), and indirect costs due to 
morbidity (25%) and mortality (18%) (Leigh et al 2002).
The long-term cost-effectiveness of programs for abate-
ment of environmental pollution is much more difﬁ  cult to 
assess, even though the reduction in NO2 concentration to a 
proposed level of 25 ppb could yield savings in mean direct 
out-of-pocket expenses per capita for treatment of persistent 
cough, persistent cough and phlegm, and wheeze in children 
of US$6.80–7.90 billion, and reduce average work/school 
days lost per capita by 3.1–5.5 days (Duki 2003).
Early diagnosis
The low attention from public health decision makers together 
with a lack of awareness among healthcare professionals and 
physicians of recommended procedures are the main reasons for 
the persistent insufﬁ  cient approach to COPD in recent decades, 
even in most industrialized and advanced countries.
Despite the heavy impact of COPD in terms of morbidity, 
mortality, and total costs on populations worldwide, COPD 
still represents a disease condition largely under-diagnosed 
during the earliest stages and under-estimated in the more 
severe phases (Rennard et al 2002; Dal Negro et al 2003a; 
European Lung White Book 2003).
The still insufﬁ  cient use of diagnostic, staging, and moni-
toring procedures (such as spirometrical tests) is conﬁ  rmed by 
the still negligible proportion of resources used for diagnosis 
and investigation (only 5%–6% of total healthcare direct costs 
for COPD) (Britton 2003; Dal Negro et al 2008).
Under-recognition is particularly damaging in terms of 
both incidence and morbidity of COPD, also contributing to 
the consequent unawareness and to inappropriate manage-
ment of the disease (Rennard et al 2002; European Lung 
White Book 2003; Dal Negro et al 2003a).
Even though lung function outcomes (ie, FEV1 changes) 
do not mirror the severity of respiratory symptoms and 
clinical changes perceived by patients in real life (see above), International Journal of COPD 2008:3(1) 5
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the disease staging needs these lung function measures. In 
practice, all interventional strategies aimed at COPD control 
should be accompanied by lung function measures in order 
to provide objective indices for assessing and monitoring 
all events and outcomes. When widely adopted in most 
patients in whom COPD is suspected, this approach will ﬁ  t 
international guidelines better.
One study aimed to assess the cost-effectiveness of early 
diagnosis of COPD showed that the cost for each diagnosed 
case (by means of spirometry, reversibility, and bronchial 
hyperreactivity measures) was US$564, lower than the 
cost of screening programs for different diseases (van den 
Boom et al 1998). Obviously, a better knowledge of the 
disease would induce an immediate higher use of healthcare 
resources following the screening program, but the net results 
of this approach should not be assessed in the short term: the 
potential long-term advantages of early interventions should 
be taken into account, and the corresponding costs diluted in 
a long-term vision for interventional strategies.
Reduction of hospital costs
Data that permit an estimate of such costs should ideally be 
produced to reﬂ  ect faithfully the true burden of COPD and 
to provide fully credible data to health care institutions.
From this arises the importance of observational studies 
and modeling on health outcomes, aimed not only at reducing 
costs but also at improving the management of COPD and 
optimizing the use of resources.
Further to prevention and early diagnosis, the health care 
organization is another cornerstone for planning an effective 
strategy against COPD.
Patients, health institutions, and society value highly 
hospital admissions and hospital stay. However there is 
a worldwide tendency to reduce hospitalizations, and in 
all industrialized countries, health care policy is aimed at 
reducing hospital admissions and their duration for acute 
diseases. But hospital admission still represents an opportunity 
for the vast majority of more severe cases, and for older 
patients, particularly during the last few years of their life 
(Andersson et al 2006), to face their own acute problems, 
and offers other possibilities for assistance scarcely or only 
anecdotally noted (such as domiciliary hospitalization, 
telemedicine). In particular, it should be taken into account 
that the most expensive 20% of COPD patients (likely the 
most severe) account for 74% of total health-care costs of the 
disease (Strassels et al 2001). However, it should be taken into 
account that patients with poor prognosis make abundant use 
of hospital services (Kinnunen et al 2006).
The results of domiciliary treatment of COPD are still 
debated and depend on several variables, such as a country’s 
health care model; the clinical severity of patients admitted; 
and the organizational pattern of home assistance (Bergner 
et al 1998; Jones et al 1999). Data from these studies proved 
that the economic advantages can be negligible when 
all indirect costs (due to both the patient’s and family’s 
involvement) are considered. Other experiences produced 
more encouraging data particularly in terms of efﬁ  cacy and 
duration of treatments, re-admissions in the 60 days follow-
ing the patient’s discharge, and deaths (Cotton et al 2000; 
Gravil et al 1998), with a reduction of direct costs of £850 
(Cotton et al 2000) and by 38% (MacIntyre et al 2002) per 
patient domiciliary treated. However, all these studies were 
carried out on small samples of patients and produced data 
that cannot be generalized.
Telemedicine has also been used in the past decade in 
several countries for the domiciliary management of chronic 
respiratory patients. Even though some aspects are still debated 
(such as the regulatory aspects of responsibilities), the clinical 
convenience of this model of assistance and the optimization 
of outcomes (both clinical and economic) were proved in 
more severe stages of COPD (Micheletto et al 1994; Dal 
Negro 2000; Agha et al 2002). In particular, in severe patients 
treated with long-term oxygen and home assisted for an 
average period of 6 years, telemetric management dramatically 
reduced direct costs (such as number of hospitalizations and 
their duration, healthcare resources, and drug use) and indirect 
costs (such as work days off for still-working subjects), starting 
in the ﬁ  rst year of remote assistance at home (Micheletto 
et al 1994; Dal Negro 2000; Ravasio et al 2005). Moreover, 
morbidity and mortality due to infectious events also dropped 
signiﬁ  cantly, so contributing to a further optimization of 
clinical (symptom relief, health status, and quality of life) 
and economic outcomes (Micheletto and Dal Negro 2005). 
The cost-effectiveness of this particular telemetric approach 
has been conﬁ  rmed in the last two decades, thus stimulating 
the interest of decision makers and healthcare institutions 
in several countries. Evidently, the keystone for the perfect 
functioning of any telemetric model is perfect organization 
among all actors involved in the model, such as the institutional 
healthcare environment, medical stuff, nurses, technological 
partners, and families of severe COPD patients, which are all 
responsible for results and outcomes optimization. A quite 
recent study further conﬁ  rmed the economic convenience of 
home telehealth programs for chronically ill patients, in which 
patient outcomes (health status and morbidity) were improved 
at a lower cost (Finkelstein et al 2006).International Journal of COPD 2008:3(1) 6
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Treatment of disability
Pulmonary rehabilitation has been deﬁ  ned as a multidisci-
plinary program of care for patients with chronic respiratory 
impairment that is individually tailored and designed to opti-
mize physical and social performance, and autonomy.
COPD is a disabling disease and the relevance of physical 
rehabilitation for improving patients’ health status in all stages 
of the disease is now well accepted (Pauwels et al 2001).
In recent years, speciﬁ  c studies proved that long-term 
rehabilitative programs signiﬁ  cantly reduce hospital admis-
sions and COPD exacerbations (Foglio et al 1999, 2001; 
Grifﬁ  ths et al 2000). Furthermore, a controlled randomized 
study conﬁ  rmed that a 2-month course of physical rehabili-
tation signiﬁ  cantly reduces hospitalizations with a shorter 
hospital stay, and number of domiciliary medical visits in the 
year following rehabilitation (Grifﬁ  ths et al 2000).
The cost-effectiveness of rehabilitation in COPD was also 
proved and it was assessed that the US$23,000 needed per 
year of good quality life (QALY) is much lower than that for 
a coronary by-pass or for mammographic screening programs 
(Toevs et al 1984; Kaplan and Ries 1996). Moreover, when 
rehabilitation was added to other interventional programs for 
COPD control, the savings in terms of therapeutic resources 
was £152 (Grifﬁ  ths et al 2001).
Hospital or domiciliary rehabilitation likely lead to dif-
ferent long-term results, even if a recent paper proved that 
a short hospital rehabilitative course of 12 sessions concen-
trated over 3 weeks gives the same results as a longer reha-
bilitative course of 8 weeks carried out in the outpatients’ 
department (Clini et al 2001).
From a general point of view, physical rehabilitation 
represents world wide an intervention capable of affecting 
signiﬁ  cantly the major COPD outcomes, such as those from 
both a patient (such as dyspnea and symptom relief, daily 
activities, quality of life, and disability) and a healthcare 
institution perspective (Tinlelman et al 2005).
Pharmacological treatments
According to the ATS/ERS deﬁ  nition, COPD is a preventable 
and treatable disease state characterized by airﬂ  ow limitation 
that is not fully reversible (Celli and MacNee 2004). The old 
views of COPD were magically deleted by this deﬁ  nition 
and it was then no longer regarded as an orphan condition 
without any opportunity for control.
By means of this consensus document, it was stated that 
even though changes in airway patency still represent the 
ﬁ  rst-line and widely used indicator (ie, FEV1) for assessing 
efﬁ  cacy and effectiveness of treatments, other indices should 
be regarded as much more suitable and reliable criteria for 
such a multifactorial disease as COPD. As previously men-
tioned, changes in FEV1 following bronchodilators can be 
small but they are often accompanied by larger changes in 
lung volumes, which contribute to a reduction in perceived 
breathlessness.
Outcomes other than only basal and post-bronchodilator 
airway obstruction can then be collected and monitored with 
the aim of providing more reliable criteria for assessing 
and comparing the therapeutic convenience of different 
pharmacological interventions or strategies. In other words, 
while spirometric classiﬁ  cation of COPD has proved useful in 
predicting outcomes such as health status and mortality, other 
indicators, such as dyspnea, BMI (21 kg/m2), and exercise 
capacity, should be introduced for a better and much suitable 
detection of COPD impact (Celli and MacNee 2004).
According to GOLD guidelines and in order to optimize 
outcomes, the pharmacological approach to COPD is progres-
sively increasing and in proportion to clinical severity.
In general terms, effective medications for COPD are 
available and all patients who are symptomatic should be sub-
mitted to a course of drug treatment. Medications currently 
available can reduce or abolish symptoms, increase exercise 
capacity, reduce the number and severity of exacerbations, 
and improve health status and quality of life, even though at 
present no treatment has been documented as being able to 
modify signiﬁ  cantly the rate of decline in lung function.
Bronchodilators represent the most effective and safe 
pharmacological option for controlling COPD symptoms in 
the vast majority of patients: even if changes in spirometrical 
ﬂ  ows following short-acting β2 agonists can be small, they 
are often accompanied by sensible changes in lung volumes 
which contribute to a signiﬁ  cant reduction in perceived 
breathlessness. It has also been shown that combining differ-
ent agents leads to a greater positive change in lung function 
and symptoms.
In general, both short-acting β2 agonists and anti-
cholinergics, when combined, have been proven to affect 
basal lung function much more than each single drug used 
alone, exercise tolerance, consumption of reliever drugs prn, 
quality of life, absenteeism, and exacerbations (Friedman 
et al 1999; Dahl et al 2001).
Regular treatment with long-acting β2 agonists and/or 
anticholinergic bronchodilators were deﬁ  ned as more conve-
nient and more effective by the last version of GOLD guide-
lines, even though they represent a more expensive choice 
(such as in terms of drug cost) than older molecules; their 
impact on several intermediate outcomes (such as, symptoms, International Journal of COPD 2008:3(1) 7
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rescue medications, increasing time between exacerbations, 
and health status) should nonetheless substantially reduce 
total COPD costs. It should also be emphasized that exacer-
bations requiring hospital admission induce a 3%–4% short-
term mortality, and that 50% of those hospitalized patients 
are re-admitted in the next 24 weeks (McCrory et al 2001). 
Furthermore, salmeterol was shown to induce a signiﬁ  cant 
amelioration in quality of life in COPD patients when regu-
larly treated (Jones 1997). Moreover, when compared with 
short-acting anticholinergics and placebo, tiotropium has 
been shown to improve health status, to reduce frequency of 
exacerbations, and to decrease hospital admissions (Casaburi 
et al 2002; Vicken et al 2002).
Long-acting bronchodilators (β2 adrenergics and tiotro-
pium) have been shown to lead to a further optimization of 
major outcomes and to the minimization of resource con-
sumption, probably because of better compliance and adher-
ence to phamacological protocols of treatment. Despite the 
increase in direct costs derived from the higher prices of most 
recent drugs, the overall cost-of-illness is decreasing substan-
tially, mainly due to a consistent drop in number of hospital 
admissions and number of visits to emergency departments, 
and reduced consumption of rescue treatments.
Despite a greater change in lung function (Zuwallack 
et al 2001), when theophylline (a weak bronchodilator, with 
a narrow therapeutic index) is added to long-acting bron-
chodilators the net effect on these outcomes did not change 
signiﬁ  cantly despite a substantial increase in costs ( 350 
patient/year), which was mainly due to laboratory tests to 
check and monitor theophylline plasma levels periodically 
(Hilleman et al 2000).
Even though COPD has been deﬁ  ned as an inﬂ  ammatory 
disease, the use of steroids in COPD is still debated mainly 
due to their inability to affect the progressive decline in lung 
function (FEV1) (Pauwels et al 1999; Burge et al 2000; Lung 
Health Study Research Group 2000; D’Souza et al 2006). 
Nonetheless, GOLD guidelines suggest the regular use of 
steroids in advanced COPD patients in whom steroids were 
previously documented as effective in terms of symptom 
relief, lung function, and health status (Coyle and Lee 1998; 
Pauwels et al 2001). However, when severe patients are 
uncontrolled by regular treatments, adding inhaled corticos-
teroids to treatment represents a justiﬁ  able and common pro-
cedure. Even though the true effectiveness of inhaled steroids 
on major outcomes of COPD has still to be clariﬁ  ed, a few 
years ago a pivotal study carried out on a large institutional 
database pinpointed the role of inhaled steroids regularly used 
for at least some weeks per year in substantilally reducing 
number deaths (Soriano et al 2003). The value of inhaled 
corticosteroids in COPD (according to disease severity) was 
also investigated a few years ago by means of health economic 
models (Borg et al 2004), and particularly in elderly COPD 
patients (Schmier et al 2005), but the scientiﬁ  c community is 
still waiting for further data for deﬁ  nitive conclusions.
Health economic modeling to compare pharmacological 
maintenance strategies in COPD is not commonly used. As 
previously mentioned, health economic models were used to 
assess the value of inhaled corticosteroids in COPD according 
to disease severity (Sin et al 2004). A particular probabilis-
tic model (such as the Markov model) was also employed 
for investigating the role of long-acting anticholinergics in 
patients with COPD over a long period of time (Borg et al 
2004; Oostenbrink et al 2004; Spencer et al 2005).
As current practice guidelines for treating COPD recom-
mend the use of combined inhaled corticosteroids and long-
acting bronchodilators in severe and very severe patients 
(GOLD stages III and IV), the value of this pharmacological 
option was also investigated by means of the same proba-
bilistic model (Iannazzo et al 2005), in order to assess the 
economic and clinical impact of this recommendation, the 
affordability of its widespread application, as well as the rela-
tive pharmacoeconomic performance of the available options 
for severe and very severe COPD. Published data on the 
Italian COPD population were ﬁ  tted in a disease progression 
model based on a Markov chain representing severity stages 
and death. Alternative therapeutic options (salmeterol/ﬂ  uti-
casone [S/F], formoterol/budesonide [F/B], salmeterol alone, 
[S], ﬂ  uticasone alone [F], and control [C]) were represented 
as competing arms in a decision tree. Efﬁ  cacy data from 
international trials were expressed in terms of risk reduction. 
Clinical parameters used were number of exacerbations and 
symptom-free days. Direct and indirect costs were considered 
and valued according to current prices and tariffs. Analyses 
were conducted from National Health Service, societal, and 
patient perspectives with time horizons of 1, 5, 10 years, 
and life-long. Mean survival of the cohort was 11.5 years. 
The C and F strategies are dominated (ie, were associated 
with worse outcomes and higher costs) by all alternatives. 
S/F and F/B were the most effective strategies, with a slight 
clinical superiority of S/F, but they were also marginally more 
expensive than S. Incremental cost/effectiveness of S/F vs 
S was  679.5/avoided exacerbation and  3.3/symptom-free 
day. The recommended use of combined inhaled corticos-
teroids and long-acting bronchodilators for severe and very 
severe COPD patients proved capable of improving clinical 
outcomes without increasing health care costs.International Journal of COPD 2008:3(1) 8
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In an observational study over a 36-month period, it was 
shown that when compared with both single components, 
corticosteroids and long-acting bronchodilator combination 
leads to a much better optimization of both life expectancy 
and costs, thus further conﬁ  rming the cost-effectiveness of 
this pharmacological strategy (Gagnon et al 2005).
New pharmacoeconomic analyses are providing some 
new speciﬁ  c indices for assessing and representing more 
precisely the greater convenience of therapeutic choices. 
ICOR, the additional cost required to produce an additional 
unit of outcome, has been used in a recent study for deﬁ  ning 
a cost-effectiveness plane, which is now regarded as a much 
more complete way for assessing economic convenience 
between different pharmacological options (Drummond 
et al 1997).
As exacerbations represent one of the major intermediate 
outcomes of COPD management, and can affect quality of 
life (Seemungal et al 1998), several studies have focused on 
the therapeutic convenience of approaching this particular 
issue and assessed the corresponding pharmacoeconomic 
impact of different pharmacological strategies in the past 
few years.
Some pivotal controlled studies are suggesting the long-
term use (usually 1 year) of combined inhaled β2 adrenergics 
and steroids as particularly convenient in reducing both 
frequency and severity of COPD exacerbations when taken 
regularly (Calverley et al 2003b, c; Dal Negro et al 2003b; 
Szafransky et al 2003), concomitantly with improved quality 
of life and increased number of symptom-free days. As exac-
erbations represent the main cause of hospital admission for 
most severe COPD patients, this therapeutic performance led 
also to a substantial optimization of all economic outcomes. 
The appropriate and long-term use of combination therapies 
proved equally tolerated, effective, and cost-effective inde-
pendently of the different molecules employed, their regular 
long-term use being the only variable that seems to play a 
relevant role in inducing positive results.
Also the regular long-term use of anti-cholinergics has 
been conﬁ  rmed to affect positively the number of exacerba-
tions and their severity (Dahl et al 2001).
COPD is a multifactorial disease characterized by several 
co-morbidities (mainly cardiovascular and metabolic) which 
contribute signiﬁ  cantly to patient survival (Mannino 2002). 
The ﬁ  rst pivotal, long-term, multicenter international trial 
carried out in order to investigate the effect of combination 
therapy on severe COPD patients’ survival proved that the 
number of deaths (due to all causes) drop by 17.5% only 
following regular treatment for 3 years with β2 adrenergics 
plus steroids, but not with a placebo or with each single 
component alone (Calverley et al 2006; Celli et al 2003). This 
extremely important outcome was obtained concomitantly 
with a substantial reduction in number of exacerbations 
(mild and severe exacerbations) and to the optimization 
of all other intermediate outcomes, such as improved lung 
function, symptom relief, health status, and improvement 
in quality of life.
The key message from all these most recent controlled 
studies carried out on large number of patients worldwide 
is that the prompt diagnosis of disease and disease exacer-
bations (Wedzicha and Wilkinson 2006), together with the 
appropriate and long-term therapeutic approach to COPD 
patients, represent the only strategy to optimize all outcomes 
related to the disease and to reduce substantially the impact 
of COPD on patients, healthcare institutions, and society.
At present, the under-diagnosis, the under-consideration, 
and the under-treatment of COPD still represent the main 
cause of ever increasing disease-induced direct and indirect 
costs; treatment failure due to inappropriate or insufﬁ  cient 
therapeutic approach is the main cause of growing COPD 
morbidity and mortality.
Despite the number of functional, clinical, and humanistic 
indicators presently used for assessing and monitoring the 
effects of interventional strategies against COPD (Jones and 
Agusti 2006), newer markers and more reliable outcomes 
should be sought in the near future in order to provide 
more precise and optimal economic outcomes for COPD 
management.
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